Skip to main content

Press releases | August 23, 2022

Fried Frank acted as counsel to Aerie Pharmaceuticals, Inc. (Aerie) in its $904 million sale to American Swiss ophthalmology company, Alcon. This transaction combines Aerie's best-in-class glaucoma franchise with Alcon's established expertise in development and commercial execution, and affirms Alcon's commitment to the ophthalmic pharmaceutical space. The transaction is expected to close in the fourth quarter of 2022.

The Fried Frank team was led by corporate partners Steven G. Scheinfeld and Matthew V. Soran, and executive compensation & ERISA partner Amy L. Blackman, and included corporate partners Andrew B. Barkan and Darren A. Littlejohn; antitrust and competition partner Nathaniel L. Asker; intellectual property and technology partner Amir R. Ghavi; litigation partner Samuel P. Groner; tax partner Alan S. Kaden; antitrust and competition special counsel Neda Moussavi; corporate associates Whitney J. Dumeng, Ryan T. Fung, Shweta Kapoor, Thomas C. Katsiotas, P. Ryan Messier, Cassidy Schuma, Colum J. Weiden, Tyler C. Winters and Josh Xiong; antitrust and competition associates Nathaniel Bronstein, Romain Girard and Brendon L. Walsh; intellectual property and technology associate Justin P. Charles: executive compensation & ERISA associate Nanci R. Kraus; litigation associate Arthur Kutoroff; and tax associate Matthew Tollin.


This communication is for general information only. It is not intended, nor should it be relied upon, as legal advice. In some jurisdictions, this may be considered attorney advertising. Please refer to the firm’s data policy page for further information.